Trial Profile
A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Bucelipase alfa (Primary)
- Indications Malabsorption syndromes
- Focus Registrational; Therapeutic Use
- Acronyms BVT.BSSL-030; LAIF
- Sponsors Swedish Orphan Biovitrum
- 09 Dec 2022 This trial has been completed in Czech Republic, Hungary and United Kingdom according to European Clinical Trials Database record.
- 31 Oct 2014 Status changed from active, no longer recruiting to discontinued according to ClinicalTrials.gov record.
- 07 Jul 2014 Planned End Date changed from 1 Aug 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.